Modalis Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to…
We are thrilled to announce a new clinical workshop focused on establishing subtype-specific care recommendations for LAMA2-RD, and using this experience as a prototype to develop recommendations for…
In 2022, Dr. Nicol Voermans and her team at Radboud UMC, Netherlands, launched the LASTSTRONG natural history study. With new…
Modalis Therapeutics has made significant strides in developing a gene therapy technology aimed at treating LAMA2-congenital muscular dystrophy (LAMA2-CMD). Earlier…
LAMA2-France and Partners launch landmark LAMA2-CMD natural history study in France. The first French natural history study focused on LAMA2-CMD…
SEAL Therapeutics was established in late 2021 by Prof. Markus Rüegg, Dr. Judith Reinhard, both from the Biozentrum, and Dr.…
